Back to Today's briefing
Health·Google News - Business·8/26/2026, 5:16:00 PM·
FDA approves landmark pancreatic cancer drug that’s shown to improve survival - AP News
The FDA has approved daraxonrasib, a groundbreaking targeted therapy for pancreatic cancer that has demonstrated improved survival rates in clinical trials. This marks a significant milestone in treating one of the deadliest forms of cancer, representing the first drug of its kind specifically designed to address certain genetic mutations found in pancreatic tumors.
AI-generated summary. Social Pulse does not publish the full article. This brief is a neutral paraphrase by AI. Read the original at Google News - Business using the link below.
Related briefs
- Reuters - World (Google News)Revolution Medicines gets FDA nod for targeted pancreatic cancer drug - Reuters
- Google News - BusinessF.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer - The New York Times
- Google News - HealthFlorida Moves to Let Children Attend School Without 4 Previously Required Vaccines - Currently.com
- Google News - HealthWhat We Know About Australia’s Bird Flu, Which Has Crossed Over to Mammals - The New York Times
- Google News - BusinessFDA approves new blood test for Alzheimer’s disease - The Hill
- Google News - HealthThese Babies Grew Up With Strict Sugar Limits. Decades Later, The Results Are Dramatic. - ScienceAlert
COMMENTS · 0
Join the conversation
Be the first to comment.
